Lysenkoism 2.0 and the Dismantling of the NIH

Note: “Lysenkoism 2.0” is used here as an analytical metaphor, not as a claim that modern America is identical to Stalin-era Soviet rule. The comparison is about what happens when political loyalty begins to outrank evidence, peer review, and scientific independence.

The National Institutes of Health was never designed to be glamorous. It does not throw confetti when a microscope works. It does not trend on social media when a grant review panel meets on time. Yet for decades, the NIH has been one of the quiet engines behind cancer therapies, vaccines, treatments for rare diseases, mental-health research, biomedical training, and the slow, unsexy work of figuring out why human bodies sometimes behave like malfunctioning Wi-Fi routers.

That is why the recent turmoil around NIH funding, grant terminations, proposed restructuring, delayed reviews, and political intervention in science matters so much. The issue is bigger than one budget fight or one agency memo. It is about whether medical research remains governed by evidence, transparent review, and long-term public benefitor whether it becomes vulnerable to ideological filtering, political retaliation, and short-term cost-cutting that mistakes scientific infrastructure for bureaucratic clutter.

What Was Lysenkoism, and Why Does It Still Haunt Science?

To understand the phrase “Lysenkoism 2.0,” it helps to rewind to the Soviet Union. Trofim Lysenko was an agronomist who rejected mainstream genetics and promoted theories that fit the political mood of Stalin’s government. He claimed that acquired characteristics could be inherited and argued that plants could be “trained” into becoming hardier in ways that genetic science did not support.

Normally, bad scientific ideas are corrected through experiments, criticism, replication, and the occasional awkward conference question from someone who has clearly had too much coffee. Lysenkoism did not follow that route. It became politically protected. Geneticists who challenged it were marginalized, fired, imprisoned, or worse. The problem was not merely that Lysenko was wrong. Science has always had wrong people, wrong papers, wrong hypotheses, and wrong PowerPoint slides. The disaster came when political power made disagreement professionally dangerous.

Under Lysenkoism, evidence became secondary to ideological usefulness. Scientific institutions were pressured to reward conclusions that aligned with official doctrine. Research that contradicted the preferred narrative was treated not as a necessary challenge but as sabotage. Soviet genetics lost years of progress because political loyalty became more valuable than scientific accuracy.

Why the NIH Matters More Than Most Americans Realize

The NIH is the largest public biomedical research funder in the United States. Its work supports university laboratories, medical schools, hospitals, clinical trials, early-career researchers, public-health studies, and disease-specific research programs that private investors often ignore because there is no obvious quick profit.

A pharmaceutical company may invest heavily in a drug with blockbuster potential. But who pays to study why rural patients cannot access cancer care? Who funds research into rare childhood disorders that affect only a few thousand people? Who supports long-term studies on environmental exposure, maternal health, vaccine confidence, substance use, dementia, or the social conditions that make some communities more vulnerable to disease?

Often, the answer is the NIH.

NIH grants do not simply pay for a scientist in a white coat to stare thoughtfully at a test tube. They fund research staff, laboratories, patient recruitment, data security, ethics review boards, imaging equipment, animal-care facilities, statistical support, computing systems, compliance requirements, clinical-trial coordination, and the electricity needed to keep the freezers from transforming years of biological samples into expensive soup.

In other words, biomedical research has direct costs and indirect costs. Direct costs buy the research itself. Indirect costs help maintain the environment that makes the research possible. A lab cannot run a clinical trial on goodwill, inspirational posters, and one heroic printer that jams every Tuesday.

The New Pressure on NIH Science

Grant Terminations and Political Priorities

Beginning in 2025, NIH research funding became entangled with broader political efforts targeting diversity initiatives, gender-related research, vaccine research, international collaboration, and studies involving populations considered politically controversial. The Government Accountability Office reported that NIH terminated more than 1,800 grants between February and June 2025 after executive actions and agency directives targeting certain categories of federally funded work.

That number matters because grants are rarely interchangeable. A canceled study is not like canceling a streaming subscription. Research projects often involve years of preparation, trained staff, patient participants, laboratory materials, community relationships, and complex ethical approvals. When funding disappears midstream, the damage is not confined to a spreadsheet. It can disrupt trials, scatter research teams, delay treatments, and discourage young scientists from building careers in fields that suddenly seem politically radioactive.

A JAMA Internal Medicine analysis found that hundreds of NIH-funded clinical trials lost grant support after termination actions in 2025. The researchers also warned that available records may understate the full impact because funding freezes and administrative delays are harder to identify than formal terminations.

The Indirect Cost Fight

One of the most controversial proposals involved capping NIH indirect-cost reimbursements at 15 percent. Supporters argued that universities had become too dependent on overhead payments and that taxpayers deserved tighter control over institutional spending. Critics countered that a universal cap ignored the real differences between institutions and would damage the laboratories, compliance systems, patient-care infrastructure, and research facilities that grants depend on.

The proposed cap became a major legal and political battle. Courts blocked the policy, concluding that NIH could not simply override negotiated research-cost arrangements that had long been governed by federal rules and congressional direction. The administration later stepped back from its effort to impose the cap, but the episode showed how quickly a seemingly technical budget decision could threaten research capacity across the country.

There is a reasonable debate to be had about university overhead, administrative bloat, and whether research institutions spend public money efficiently. Every public system should face scrutiny. But auditing a system is not the same as smashing the instruments and announcing that the orchestra is now leaner.

The Proposed Restructuring of NIH

The administration’s fiscal year 2026 budget request proposed reducing NIH funding to roughly $27.9 billion and restructuring the agency’s 27 institutes and centers into a smaller number of entities. Supporters framed the proposal as a way to streamline government, reduce duplication, and align research priorities with a new health agenda. Critics warned that collapsing specialized institutes could weaken disease-specific expertise, disrupt grant programs, and create confusion across the biomedical research system.

It is important to separate proposal from outcome. Congress did not simply accept every recommended reduction. Reporting on the fiscal year 2026 appropriations process indicated that NIH ultimately received funding well above the administration’s proposed level. That distinction matters because public debate often turns budget proposals into accomplished facts before Congress, courts, and agencies have finished arguing about them.

Still, the proposed reduction revealed a governing philosophy: biomedical research could be treated less as long-term national infrastructure and more as a flexible line item that can be dramatically reconfigured according to political preference. That is where the Lysenkoism comparison becomes uncomfortable.

What “Lysenkoism 2.0” Really Means

Calling something “Lysenkoism” should not be a lazy way to insult anyone who disagrees about public spending, public health, diversity programs, or research priorities. Governments have a legitimate role in setting broad funding goals. Taxpayers have a legitimate interest in accountability. Scientists are not entitled to operate in a magical budget cloud where no one asks questions.

The danger appears when political leaders move from setting priorities to predetermining acceptable conclusions.

Lysenkoism begins when scientific research is judged not by whether it is methodologically sound, transparent, reproducible, and useful, but by whether it produces politically convenient answers. It grows when terms such as “waste,” “ideology,” “bias,” or “anti-American” become shortcuts for eliminating entire categories of research before the evidence has been examined.

Research on HIV prevention, maternal mortality, health disparities, vaccine misinformation, mental health, gender-related care, addiction, environmental exposure, and infectious disease may be politically uncomfortable in different ways. But discomfort is not a scientific method. A disease does not stop affecting people because a budget document decides its name is awkward.

For example, public-health research often studies groups at elevated risk because that is where the harm is concentrated. If researchers cannot study vulnerable populations without being accused of ideological favoritism, the result is not neutrality. The result is a blind spot with a grant number attached. KFF reporting has documented the termination of NIH-supported HIV research grants, including projects involving prevention and access to care for populations disproportionately affected by the virus.

The Difference Between Reform and Dismantling

Reform asks difficult questions and improves the system. Dismantling creates instability so deep that the system cannot reliably perform its mission.

Reform might include stronger transparency around indirect costs, clearer grant evaluation criteria, reduced administrative burden, better support for early-career scientists, stronger safeguards against conflicts of interest, and more public reporting on research outcomes. Those changes could make NIH funding more accountable without weakening the scientific process.

Dismantling looks different. It involves abrupt cancellations, opaque decisions, politically targeted grant categories, delayed peer review, staff losses, shifting rules, and budget threats that make long-term planning nearly impossible. Science is already slow because reality is stubborn. It becomes much slower when researchers must also guess whether their next project will survive the political weather forecast.

One of the most damaging effects is uncertainty. A senior professor may survive a funding disruption by drawing on institutional reserves or long-standing collaborations. A postdoctoral researcher, a junior faculty member, or a laboratory technician may not. When a young scientist watches mentors lose grants, cancel projects, or leave research entirely, that person may decide not to enter the field at all.

That loss is not always visible in annual budget documents. It shows up years later as the cancer researcher who became a consultant, the epidemiologist who moved abroad, the clinical coordinator whose job disappeared, or the graduate student who decided biomedical research was too fragile to build a life around.

Why the United States Is Not the Soviet Unionand Why That Should Matter

The United States still has protections that Soviet scientists did not. Courts can block unlawful actions. Congress controls appropriations. Journalists can investigate. Scientific societies can criticize policy. Researchers can sue, organize, publish, and testify. Independent universities, nonprofit organizations, professional associations, and state governments can challenge federal decisions.

Those institutions have already mattered. Courts blocked the NIH indirect-cost cap, judges ruled against some grant cancellations, and public reporting forced greater scrutiny of the effects of funding disruptions.

But the existence of guardrails does not mean there is no danger. A bridge can have guardrails and still be a terrible place to drive at 90 miles per hour in a thunderstorm. The point is not that the NIH has vanished. The point is that repeated shocks can weaken the research ecosystem long before anyone formally announces that it has been dismantled.

What a Healthier NIH Debate Would Look Like

A serious conversation about NIH reform should begin with a shared principle: science needs independence, but public institutions also need accountability.

That means lawmakers should demand transparent evidence for major structural changes. They should distinguish between eliminating genuine waste and eliminating research topics that make politicians uncomfortable. They should protect peer review from partisan interference. They should require clear public explanations when grants are terminated. They should support predictable multiyear funding so laboratories can plan responsibly.

Most importantly, policymakers should remember that the NIH is not just a federal agency. It is a nationwide network of hospitals, universities, laboratories, patients, caregivers, trainees, and communities. Every decision about its future affects more than bureaucratic charts. It affects whether a clinical trial continues, whether a rare disease gets studied, whether a public-health crisis is detected early, and whether the next generation believes science is still a viable public calling.

Experiences From the Research Front Line

The following experiences are composite scenarios based on publicly reported disruptions in NIH funding, grant reviews, clinical trials, and university research operations. They are illustrative, not accounts of specific identifiable individuals.

The Lab Manager and the Frozen Hiring Plan

Imagine managing a university laboratory that studies why certain communities have higher rates of diabetes complications. The project has funding, staff, a timeline, and partnerships with clinics that have spent years building trust with patients. Then the grant is flagged because the proposal uses language related to health disparities.

No one tells the team exactly what will happen next. The principal investigator sends emails. The grants office sends more emails. The university lawyer sends the kind of email that makes everyone suddenly very interested in reading attachments. Meanwhile, a research assistant needs to know whether she still has a job in three months.

The project may eventually survive. A court may intervene. The agency may reverse a decision. But scientific work does not pause neatly. Participants move away. Staff accept other jobs. Clinics lose confidence. Data collection windows close. Trust, which took years to build, can evaporate faster than a budget justification.

The Clinical Trial Coordinator and the Patient Calendar

Clinical trials are often discussed as if they are abstract items in a grant database. In reality, they are calendars full of human beings. A coordinator may be scheduling scans, blood tests, follow-up calls, travel reimbursement, medication monitoring, and safety reporting for patients who are already frightened by a diagnosis.

When funding becomes uncertain, the coordinator cannot simply say, “Science is on hold until the spreadsheet feels better.” Patients need answers. Physicians need to know whether the study can continue. Researchers must decide whether to enroll new participants, delay treatment arms, or reduce staff.

That is why abrupt grant termination can be especially disruptive. Even when patient care continues through other resources, the research process becomes unstable. The result is not always a dramatic headline. Sometimes it is a postponed appointment, a missed data point, a research nurse who leaves, or a study that quietly becomes smaller than it was designed to be.

The Young Scientist Watching From the Back Row

Perhaps the most overlooked experience belongs to the early-career researcher. A graduate student may have spent five years learning advanced methods, building a dissertation project, and imagining a future in biomedical science. Then she watches grant reviews freeze, mentors lose support, and politically sensitive fields become risky career choices.

She starts asking practical questions. Should I study infectious disease? Should I focus on reproductive health? Should I work on vaccine communication? Should I avoid topics involving race, gender, poverty, disability, addiction, or public policy because the research may become politically vulnerable?

Those questions may never appear in official NIH statistics. Yet they shape the future research pipeline. If scientists begin avoiding important questions because the questions are politically inconvenient, the country does not become more neutral. It becomes less prepared.

The Taxpayer Who Thinks This Has Nothing to Do With Them

It is easy for taxpayers to hear about NIH budgets and assume the debate is mainly about elite universities fighting over money. Sometimes universities do deserve scrutiny. Sometimes bureaucracy deserves pruning. Sometimes overhead costs deserve a flashlight, a calculator, and perhaps a slightly judgmental accountant.

But the NIH’s long-term value reaches far beyond campus buildings. It affects cancer treatments, medical devices, pandemic preparedness, Alzheimer’s research, mental-health care, rare disease therapies, maternal health, addiction treatment, and the training of doctors and scientists.

The question is not whether NIH should be accountable. Of course it should. The real question is whether accountability will be built through evidence, transparency, and competent reformor through ideological suspicion, abrupt funding shocks, and a system that punishes researchers for studying inconvenient realities.

Conclusion

Lysenkoism was not merely a historical mistake about genetics. It was a warning about what happens when power decides that science must deliver approved answers. The current conflict around NIH funding does not mean America has become Stalinist. It does mean that the country should be alert when research priorities become politically filtered, when grants are canceled without transparent scientific justification, and when public-health knowledge is treated as optional because it complicates a preferred narrative.

The NIH can be reformed. It can be made more efficient, more transparent, and more accountable. But reform must strengthen scientific independence rather than weaken it. Otherwise, the United States risks replacing long-term biomedical leadership with a much cheaper product: uncertainty, brain drain, unfinished trials, and a national research system that learns to ask only the questions politics permits.